Thermo Fisher Scientific launches Gibco OncoPro Tumoroid Culture Medium Kit


Fisher Scientific, a global leader in serving science, unveiled its latest product, the Gibco OncoPro Tumoroid Culture Medium Kit to expedite development of novel cancer therapies.

This product is distinguished as the first commercially available culture medium explicitly crafted for the expansion of patient-derived tumoroids, also known as cancer organoids, from various cancer indications.

The Gibco OncoPro Tumoroid Culture Medium streamlines the cultivation process of patient-derived cancer organoids. This advancement aims to enhance the accessibility of physiologically relevant cancer models.

The culture system is designed to easily integrate into current workflows, offering an upgrade to your media without compromising results. The robust development process behind the creation of the OncoPro Tumoroid Culture Medium is attributed to Thermo Fisher’s team of scientists, backed by extensive data.

Gibco OncoPro Tumoroid Culture Medium Kit from Thermo Fisher Scientific.

Gibco OncoPro Tumoroid Culture Medium Kit from Thermo Fisher Scientific. Photo courtesy of Business Wire.

This novel media system was meticulously developed to accommodate the growth of patient-derived tumoroids. During its creation, over 40 conditions were tested to establish the optimal blend of basal media, supplements, and growth factors that would best support the long-term preservation of donor-specific characteristics such as mutational profiles and gene expression patterns.

See also  Boston Scientific to acquire Lumenis surgical business for $1bn

The OncoPro Tumoroid Culture Medium Kit is a flexible solution designed to cater to intricate research requirements. It has the capacity to accommodate multiple cancer indications with a single media kit. Furthermore, its scalable and automation-friendly suspension workflow ensures seamless transitions to various downstream assays. Omitting the use of Wnt, R-spondin, Noggin, and small molecule inhibitors, OncoPro is ideal for advanced biological studies and screening applications.

See also  One80 Intermediaries acquires life insurance broker Marcus Insurance Agency

Patient-derived tumoroids, which closely resemble donor tissue more than conventional 2D cell models, show potential in enhancing clinical trial success rates. They enable researchers to better model diseases and predict patient response to therapeutics in vitro. However, their use in cancer research has been limited due to complex culture requirements and a scarcity of commercially available media systems. Thermo Fisher’s off-the-shelf, modular tumoroid culture medium kit seeks to make these intricate cancer models more accessible to researchers.

Committed to supporting scientists in developing tumoroid workflows and protocols, Thermo Fisher is democratizing this workflow through the OncoPro Tumoroid Media system and Tumoroid Assay Development Services. These services support outsourced screening and characterization.

Additionally, customers can take advantage of seven unique OncoPro Tumoroid Cell Lines, which represent four different cancer indications including colorectal, lung, endometrial, and breast. To further enhance usability, the OncoPro Tumoroid Culture Medium Kit includes a scalable, automation-compatible suspension culture method.

See also  Is Khalistani terrorist Gurpatwant Mann Singh Pannu's death just a rumor?

Brian Douglass — Thermo Fisher Scientific vice president and general manager of cell biology said: “Cancer’s unpredictable nature presents a significant scientific and clinical challenge for future discoveries and in delivering life-saving treatments to patients.

“Globally, millions of patients and their families still await a cure for cancer despite the decades of advances in research, diagnostics and treatments aimed at helping lower cancer mortality. We developed the new OncoPro Tumoroid Culture Medium Kit so the scientific community can take greater advantage of tumoroid models to help bring drug candidates to market faster and more cost-effectively.”

Share This


Wordpress (0)